80 related articles for article (PubMed ID: 38601972)
1. A dual-receptor T-cell platform with Ab-TCR and costimulatory receptor achieves specificity and potency against AML.
Dao T; Xiong G; Mun SS; Meyerberg J; Korontsvit T; Xiang J; Cui Z; Chang AY; Jarvis C; Cai W; Luo H; Pierson A; Daniyan A; Yoo S; Takao S; Kharas M; Kentsis A; Liu C; Scheinberg DA
Blood; 2024 Feb; 143(6):507-521. PubMed ID: 38048594
[TBL] [Abstract][Full Text] [Related]
2. Trial Watch: Adoptive TCR-Engineered T-Cell Immunotherapy for Acute Myeloid Leukemia.
Campillo-Davo D; Anguille S; Lion E
Cancers (Basel); 2021 Sep; 13(18):. PubMed ID: 34572745
[TBL] [Abstract][Full Text] [Related]
3. CAR'TCR-T cells co-expressing CD33-CAR and dNPM1-TCR as superior dual-targeting approach for AML treatment.
Teppert K; Yonezawa Ogusuku IE; Brandes C; Herbel V; Winter N; Werchau N; Khorkova S; Wöhle C; Jelveh N; Bisdorf K; Engels B; Schaser T; Anders K; Künkele A; Lock D
Mol Ther Oncol; 2024 Jun; 32(2):200797. PubMed ID: 38601972
[TBL] [Abstract][Full Text] [Related]
4. Combinatorial antigen targeting strategies for acute leukemia: application in myeloid malignancy.
Atilla PA; McKenna MK; Watanabe N; Mamonkin M; Brenner MK; Atilla E
Cytotherapy; 2022 Mar; 24(3):282-290. PubMed ID: 34955406
[TBL] [Abstract][Full Text] [Related]
5. Optimization of universal allogeneic CAR-T cells combining CRISPR and transposon-based technologies for treatment of acute myeloid leukemia.
Calviño C; Ceballos C; Alfonso A; Jauregui P; Calleja-Cervantes ME; San Martin-Uriz P; Rodriguez-Marquez P; Martin-Mallo A; Iglesias E; Abizanda G; Rodriguez-Diaz S; Martinez-Turrillas R; Illarramendi J; Viguria MC; Redondo M; Rifon J; Villar S; Lasarte JJ; Inoges S; Lopez-Diaz de Cerio A; Hernaez M; Prosper F; Rodriguez-Madoz JR
Front Immunol; 2023; 14():1270843. PubMed ID: 37795087
[TBL] [Abstract][Full Text] [Related]
6. CD33-Specific Chimeric Antigen Receptor T Cells with Different Co-Stimulators Showed Potent Anti-Leukemia Efficacy and Different Phenotype.
Li S; Tao Z; Xu Y; Liu J; An N; Wang Y; Xing H; Tian Z; Tang K; Liao X; Rao Q; Wang M; Wang J
Hum Gene Ther; 2018 May; 29(5):626-639. PubMed ID: 29409351
[TBL] [Abstract][Full Text] [Related]
7. In Vitro Pre-Clinical Validation of Suicide Gene Modified Anti-CD33 Redirected Chimeric Antigen Receptor T-Cells for Acute Myeloid Leukemia.
Minagawa K; Jamil MO; Al-Obaidi M; Pereboeva L; Salzman D; Erba HP; Lamb LS; Bhatia R; Mineishi S; Di Stasi A
PLoS One; 2016; 11(12):e0166891. PubMed ID: 27907031
[TBL] [Abstract][Full Text] [Related]
8. Novel CAR T therapy is a ray of hope in the treatment of seriously ill AML patients.
Marofi F; Rahman HS; Al-Obaidi ZMJ; Jalil AT; Abdelbasset WK; Suksatan W; Dorofeev AE; Shomali N; Chartrand MS; Pathak Y; Hassanzadeh A; Baradaran B; Ahmadi M; Saeedi H; Tahmasebi S; Jarahian M
Stem Cell Res Ther; 2021 Aug; 12(1):465. PubMed ID: 34412685
[TBL] [Abstract][Full Text] [Related]
9. Automated manufacture of ΔNPM1 TCR-engineered T cells for AML therapy.
Yonezawa Ogusuku IE; Herbel V; Lennartz S; Brandes C; Argiro E; Fabian C; Hauck C; Hoogstraten C; Veld S; Hageman L; Teppert K; Koutsoumpli G; Griffioen M; Mockel-Tenbrinck N; Schaser T; de Groot R; Johnston ICD; Lock D
Mol Ther Methods Clin Dev; 2024 Jun; 32(2):101224. PubMed ID: 38516690
[TBL] [Abstract][Full Text] [Related]
10. Bispecific CD33/CD123 targeted chimeric antigen receptor T cells for the treatment of acute myeloid leukemia.
Boucher JC; Shrestha B; Vishwasrao P; Leick M; Cervantes EV; Ghafoor T; Reid K; Spitler K; Yu B; Betts BC; Guevara-Patino JA; Maus MV; Davila ML
Mol Ther Oncolytics; 2023 Dec; 31():100751. PubMed ID: 38075241
[TBL] [Abstract][Full Text] [Related]
11. The Black Hole: CAR T Cell Therapy in AML.
Atilla E; Benabdellah K
Cancers (Basel); 2023 May; 15(10):. PubMed ID: 37345050
[TBL] [Abstract][Full Text] [Related]
12. Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis.
Shahzad M; Nguyen A; Hussain A; Ammad-Ud-Din M; Faisal MS; Tariq E; Ali F; Butt A; Anwar I; Chaudhary SG; Lutfi F; Ahmed N; Singh AK; Hematti P; McGuirk JP; Mushtaq MU
Front Immunol; 2023; 14():1152457. PubMed ID: 37168849
[TBL] [Abstract][Full Text] [Related]
13. Stable expression of large transgenes via the knock-in of an integrase-deficient lentivirus.
Chavez M; Rane DA; Chen X; Qi LS
Nat Biomed Eng; 2023 May; 7(5):661-671. PubMed ID: 37127707
[TBL] [Abstract][Full Text] [Related]
14. Neoantigens: promising targets for cancer therapy.
Xie N; Shen G; Gao W; Huang Z; Huang C; Fu L
Signal Transduct Target Ther; 2023 Jan; 8(1):9. PubMed ID: 36604431
[TBL] [Abstract][Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
